Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Apimeds Pharmaceuticals US, Inc. (APUS) had Return on Tangible Equity of 2697.52% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-35.06M |
|
-- |
|
-- |
|
$12.19M |
|
$-12.19M |
|
$-22.87M |
|
$-35.06M |
|
$-13.00M |
|
$-35.06M |
|
$-35.06M |
|
$-35.06M |
|
$-13.00M |
|
$-12.19M |
|
$-12.17M |
|
15.51M |
|
15.51M |
|
$-2.26 |
|
$-2.26 |
|
| Balance Sheet Financials | |
$13.15M |
|
$0.06M |
|
$128.07M |
|
$141.22M |
|
$14.58M |
|
-- |
|
$0.12M |
|
$14.70M |
|
$126.44M |
|
$-1.30M |
|
$126.52M |
|
12.58M |
|
| Cash Flow Statement Financials | |
$-2.07M |
|
$0.49M |
|
$0.92M |
|
$9.64M |
|
$8.98M |
|
$-0.66M |
|
$0.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.90 |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.08M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-27.73% |
|
|
Return on Tangible Equity |
2697.52% |
-24.83% |
|
-27.71% |
|
$10.06 |
|
$-0.13 |
|
$-0.13 |
|